Human and rodent trans-species carcinogens often demonstrate similar organotropic patterns of neoplasia and loss of heterozygosity (LOH)[See Figure 1 and Table 1 below]. Recently, we have observed significant chromosome 11 LOH in B6.129-Trp53tm1Brd N5 mice heterozygous for a p53 null allele using simple sequence length polymorphic loci analysis (see Figure 2). Primers specific for known SSLP loci revealed amplicons consistent with the two strains, C57BL/6 and 129Sv, present in the mice. The degree of heterozygosity observed on chromosome 11was unexpected because the mice were reported to be on a C57BL/6-Trp53 (N5) background which would be approximately 3% 129Sv alleles primarily flanking the null allele (129 embryonic stem cell origin). By exploiting the observed heterozygosity on chromosome 11 in the 5th backcross generation, we learned that LOH was not restricted to theTrp53 locus as determined by Southern analysis of genomic DNA from tumors and control tissue. A complete copy of chromosome 11 of maternal origin carrying the p53 wildtype allele was lost during exposure to phenolphthalein resulting in thymic lymphomas in these mice. The investigation confirmed a chromosome 11 non-dysjunction mechanism of action for phenolphthalein as revealed by allelotype analysis based on comparison to the germline pattern of SSLP loci. Chromosome 11 loss also occurred in benzene and p-cresidine induced p53 (+/-) mouse sarcomas (oral, intubation) and thymic lymphomas (inhalation, whole animal) and bladder tumors (dietary), respectively. The results establish microsatellite (SSLP loci) mapping as a useful tool for determination of LOH in tumor studies using p53 haploinsufficient mice. We hypothesize that carcinogen induced DNA damage in the p53 haploinsufficient mice resulted in either chromosome 11 mis-segregation or recombination during induced repair processes that induced LOH resulting in genomic instability leading to neoplasia. In summary, we have shown that in independent studies that there is sufficient heterozygosity on chromosome 11 in the heterozygous p53 deficient (+/-) N5 generation mouse to use microsatellite markers at 5 cM intervals to demonstrate whole or partial chromosome loss through non-disjunction and homologous recombination.

Agency
National Institute of Health (NIH)
Institute
National Institute of Environmental Health Sciences (NIEHS)
Type
Intramural Research (Z01)
Project #
1Z01ES021207-08
Application #
6681846
Study Section
(ECP)
Project Start
Project End
Budget Start
Budget End
Support Year
8
Fiscal Year
2002
Total Cost
Indirect Cost
Name
U.S. National Inst of Environ Hlth Scis
Department
Type
DUNS #
City
State
Country
United States
Zip Code
Cullen, John M; Brown, Danielle L; Kissling, Grace E et al. (2009) Aflatoxin B1 and/or hepatitis B virus induced tumor spectrum in a genetically engineered hepatitis B virus expression and Trp53 haploinsufficient mouse model system for hepatocarcinogenesis. Toxicol Pathol 37:333-42
Qu, Wei; Ke, Hengning; Pi, Jingbo et al. (2007) Acquisition of apoptotic resistance in cadmium-transformed human prostate epithelial cells: Bcl-2 overexpression blocks the activation of JNK signal transduction pathway. Environ Health Perspect 115:1094-100
Donehower, Lawrence A; French, John E; Hursting, Stephen D (2005) The utility of genetically altered mouse models for cancer research. Mutat Res 576:1-3
MacDonald, James; French, John E; Gerson, Ronald J et al. (2004) The utility of genetically modified mouse assays for identifying human carcinogens: a basic understanding and path forward. The Alternatives to Carcinogenicity Testing Committee ILSI HESI. Toxicol Sci 77:188-94
Martin, Keith R; Jokinen, Micheal P; Honeycutt, Hayden P et al. (2004) Tumor profile of novel p53 heterozygous Tg.AC (v-Ha-ras) bitransgenic mice treated with benzo(a)pyrene and fed dietary N-acetyl-L-cysteine (NAC). Toxicol Sci 81:293-301
Martin, Keith R; Jokinen, Michael P; Honeycutt, Hayden P et al. (2004) Tumor spectrum in the p53 heterozygous zeta globin-promoted Tg.AC (v-Ha-ras) bitransgenic mouse model. Toxicol Pathol 32:418-25
French, John E (2004) Identification and characterization of potential human carcinogens using B6.129tm1Trp53 heterozygous null mice and loss of heterozygosity at the Trp53 locus. IARC Sci Publ :271-87
Nwosu, Veronica C; Kissling, Grace E; Trempus, Carol S et al. (2004) Exposure of Tg.AC transgenic mice to benzene suppresses hematopoietic progenitor cells and alters gene expression in critical signaling pathways. Toxicol Appl Pharmacol 196:37-46
Pritchard, John B; French, John E; Davis, Barbara J et al. (2003) The role of transgenic mouse models in carcinogen identification. Environ Health Perspect 111:444-54
Hulla, J E; French, J E; Dunnick, J K (2001) Chromosome 11 allelotypes reflect a mechanism of chemical carcinogenesis in heterozygous p53-deficient mice. Carcinogenesis 22:89-98

Showing the most recent 10 out of 17 publications